Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Abstract
A once-daily, fixed-dose combination of memantine extended-release (ER)/donepezil 28/10 mg (Namzaric™) is available in the USA for patients with moderate to severe Alzheimer's disease (AD) on stable memantine and donepezil therapy. The fixed-dose formulation is bioequivalent to coadministration of the individual drugs. In a 24-week, phase III trial in patients with moderate to severe AD, addition of memantine ER 28 mg once daily to stable cholinesterase inhibitor (ChEI) therapy was more effective than add-on placebo on measures of cognition, global clinical status, dementia behaviour and semantic processing ability, although between-group differences on a measure of daily function did not significantly differ. In subgroup analyses in donepezil-treated patients, add-on memantine ER was more effective than add-on placebo on measures of cognition, dementia behaviour and semantic processing, although there were no significant between-group differences on measures of global clinical status and daily function. Memantine ER plus ChEI combination therapy was generally well tolerated in the phase III trial, with diarrhoea, dizziness and influenza occurring at least twice as often with add-on memantine ER as add-on placebo in donepezil-treated patients. Thus, memantine ER plus donepezil combination therapy is an effective and well tolerated treatment option for patients with moderate to severe AD. The fixed-dose combination is potentially more convenient than coadministration of the individual agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 2014, the FDA approved a fixed-dose combination of donepezil and memantine for the symptomatic treatment of moderate-to-severe AD.
“Notably, in 2014, the Food and Drug Administration (FDA) approved a fixed-dose combination of AChE inhibitor (AChEI) donepezil (1) and NMDAR blocker memantine (2) for the symptomatic treatment of moderate-to-severe AD (Figure 4).46”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [46]
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017 · see citing works
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works
2014 Alzheimer's disease facts and figures
Alzheimer's Association (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.001 · Cited by 1,032 · see citing works
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · see citing works
Qaseem, A., Snow, V. T., Cross, J. T., Forciea, M. A., HOPKINS, R. H., Shekelle, P., Adelman, A., Mehr, D. R., Schellhase, K. G., Campos-Outcalt, D. E., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 350 · see citing works
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 337 · see citing works
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · see citing works
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · see citing works
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181 · see citing works
Grossberg, G. T., Manes, F. F., Allegri, R., Gutiérrez‐Robledo, L. M., Gloger, S., Xie, L., Jia, X., Pejović, V., Miller, M. L., Perhach, J. L., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0077-7 · Cited by 158 · see citing works
Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140 · see citing works
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126 · see citing works
Atri, A., Hendrix, S. B., Pejović, V., Hofbauer, R. K., Edwards, J., Molinuevo, J. L., & Graham, S. M. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0109-2 · Cited by 76 · see citing works
Predictors of adherence among Alzheimer's disease patients receiving oral therapy
Borah, B., Sacco, P., & Zarotsky, V. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.493788 · Cited by 67 · see citing works
Effective pharmacological management of Alzheimer's disease.
Atri, A. (2011) · PubMed · Cited by 57 · see citing works
A population-based study of dosing and persistence with anti-dementia medications
Brewer, L., Bennett, K., McGreevy, C., & Williams, D. J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1483-y · Cited by 45 · see citing works
Jelić, V., & Darreh‐Shori, T. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s5410 · Cited by 35 · see citing works
Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0400-3 · Cited by 30 · see citing works
Boinpally, R., Chen, L., Zukin, S. R., McClure, N., Hofbauer, R. K., & Periclou, A. P. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0296-4 · Cited by 22 · see citing works
Thibault, C. S., Stillman, I. Ö., Chen, S., Getsios, D., Proskorovsky, I., Hernandez, L. G., & Dixit, S. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1063501 · Cited by 20 · see citing works
Hendrix, S. B., Ellison, N., Stanworth, S., Otcheretko, V., & Tariot, P. N. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.66 · Cited by 11 · see citing works
Grossberg, G. T., Alva, G., Hendrix, S. B., Hofbauer, R. K., Pejović, V., & Graham, S. M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.612 · Cited by 4 · see citing works
Atri, A., Hendrix, S. B., Ellison, N., Pejović, V., & Otcheretko, V. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1672 · Cited by 1 · see citing works
Hendrix, S. B., Ellison, N., & Otcheretko, V. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1662 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147 · see citing works
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works
Gribkoff, V. K., & Kaczmarek, L. K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.021 · Cited by 379 · see citing works
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 314 · see citing works
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 240 · see citing works
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189 · see citing works
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works
The GABAergic system as a therapeutic target for Alzheimer's disease
Guzmán, B. C., Vinnakota, C., Govindpani, K., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14345 · Cited by 170 · see citing works
Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121 · see citing works
Sang, Z., Wang, K., Shi, J., Liu, W., Cheng, X., Zhu, G., Wang, Y., Zhao, Y., Qiao, Z., Wu, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112180 · Cited by 77 · see citing works
Classics in Chemical Neuroscience: Memantine
Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00270 · Cited by 73 · see citing works
Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease
Yamamoto, Y., Kanayama, N., Nakayama, Y., & Matsushima, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030444 · Cited by 66 · see citing works
Hall, H., Iulita, M. F., Gubert, P., Aguilar, L. F., Ducatenzeiler, A., Fisher, A., & Cuello, A. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.11.009 · Cited by 62 · see citing works
Pietrancosta, N., Djibo, M., Daumas, S., Mestikawy, S. E., & Erickson, J. D. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01912-7 · Cited by 59 · see citing works
Ávila, J., Llorens-Martı́n, M., Pallas‐Bazarra, N., Bolós, M., Perea, J. R., Rodríguez-Matellán, A., & Hernández, F. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00626 · Cited by 58 · see citing works
Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
Peterson, A. C., & Li, C.-S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00127 · Cited by 54 · see citing works
Pisani, L., Iacobazzi, R. M., Catto, M., Rullo, M., Farina, R., Denora, N., Cellamare, S., & Altomare, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.016 · Cited by 51 · see citing works
Jannat, S., Balupuri, A., Ali, M. Y., Hong, S. S., Choi, C. W., Choi, Y., Ku, J., Kim, W. J., Leem, J. Y., Kim, J. E., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0205-7 · Cited by 48 · see citing works
Martins, M. M., Branco, P. S., & Ferreira, L. M. (2023) · ChemistrySelect · doi:10.1002/slct.202300461 · Cited by 45 · see citing works
Puranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 45 · see citing works
Pérez-Areales, F. J., Turcu, A. L., Barniol‐Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., Simone, A. D., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 43 · see citing works
Nirogi, R. V. S., Abraham, R., Benade, V. S., Medapati, R. B., Jayarajan, P., Bhyrapuneni, G., Muddana, N., Mekala, V. R., Subramanian, R., Shinde, A. K., et al. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000414 · Cited by 38 · see citing works
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 36 · see citing works
Jang, C. H., Lee, S., Park, I. Y., Song, A., Moon, C., & Cho, G. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.4.495 · Cited by 35 · see citing works
Liu, Z., Qiu, X., Mak, S., Guo, B., Hu, S., Wang, J., Luo, F., Xu, D., Sun, Y., Zhang, G., et al. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109020 · Cited by 35 · see citing works
Fernández‐Bolaños, J. G., & López, Ó. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2083956 · Cited by 35 · see citing works
Yang, W., Shi, Y., Zhang, Y., Yang, Y., Du, Y., Yang, Z., Wang, X., Lei, T., Xu, Y., Chen, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09449 · Cited by 32 · see citing works
Acidity and Acid-Sensing Ion Channels in the Normal and Alzheimer’s Disease Brain
Gonzales, E. B., & Sumien, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161131 · Cited by 32 · see citing works
Sasi, V. M., Vangavolu, P., Kumar, S., & Raja, A. S. (2019) · ChemMedChem · doi:10.1002/cmdc.201900277 · Cited by 31 · see citing works
Mak, S., Li, W., Fu, H., Luo, J., Cui, W., Hu, S., Pang, Y., Carlier, P. R., Tsim, K. W. K., Pi, R., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15379 · Cited by 30 · see citing works
Metabolic regulation of synaptic activity
Fedorovich, S. V., & Waseem, T. V. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0090 · Cited by 24 · see citing works
Liu, Q., Wang, S., & Ding, K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30093-6 · Cited by 23 · see citing works
Boinpally, R., Chen, L., Zukin, S. R., McClure, N., Hofbauer, R. K., & Periclou, A. P. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0296-4 · Cited by 22 · see citing works
Li, L., Xu, S., Liu, L., Feng, R., Gong, Y., Zhao, X., Li, J., Cai, J., Feng, N., Wang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160587 · Cited by 20 · see citing works
Begines, P., Fernández‐Bolaños, J. G., & López, Ó. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2602702 · Cited by 17 · see citing works
Ye, N., Wang, Q., Li, Y., & Zhen, X. (2024) · Medicinal Research Reviews · doi:10.1002/med.22086 · Cited by 17 · see citing works
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 16 · see citing works
Driver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 15 · see citing works
Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs
Mohamed, L. W., Mohamed, K. O., Sayed, H. S., & Mahmoud, Z. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220827155615 · Cited by 12 · see citing works
Long-term use of antipsychotics in community-dwelling dementia patients
Boucherie, Q., Gentile, G., Chalançon, C., Sciortino, V., Blin, O. J., Micallef, J., & Bonin‐Guillaume, S. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000150 · Cited by 11 · see citing works
Huang, P., He, X.-Y., & Xu, M. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.67.02.20200378 · Cited by 10 · see citing works
Enhanced Anti-Amyloid Effect of Combined Leptin and Pioglitazone in APP/PS1 Transgenic Mice
Liu, Y., Hanson, K., McCormack, G. H., Atkinson, R. A. K., Dittmann, J., Vickers, J. C., Fernández-Martos, C. M., & King, A. E. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210218163857 · Cited by 9 · see citing works
Natural Products with BACE1 and GSK3β Inhibitory Activity
Prado, P. C., Lima, J. A., Hamerski, L., & Rennó, M. N. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666221118113923 · Cited by 7 · see citing works
Li, J., Zhang, F., Zhao, L., & Dong, C. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0006 · Cited by 6 · see citing works
Multiple Ligands in Neurodegenerative Diseases
Lalut, J., Rochais, C., & Dallemagne, P. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch16 · Cited by 6 · see citing works
Advancing Care in Alzheimer’s Disease: Current Treatments and Their Impact on Quality of Life
Yashaeva, L., Montoya, M., Joshi, J., Stephens, A., McNulty, O., & Kaur, G. (2025) · Cureus · doi:10.7759/cureus.90527 · Cited by 5 · see citing works
An appraisal at a glance of metallome and disease biomarkers
López, R., Pereira, F. J., & Aller, A. J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117931 · Cited by 4 · see citing works
Memantine and Alzheimer's disease
del Río‐Sancho, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00032-x · Cited by 3 · see citing works
Alzheimer’s Disease: Causes, Mechanisms, and Steps Toward Prevention
Choi, S. H., & Tanzi, R. E. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190069162.013.18 · Cited by 3 · see citing works
Bali, Z. K., Bruszt, N., Göntér, K., & Hernádi, I. (2025) · Behavioral and Brain Functions · doi:10.1186/s12993-025-00302-0 · Cited by 2 · see citing works
Role of Anti-dementia Medication
Prasher, V. P., Qureshi, K., & Fatema, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-56934-1_13 · Cited by 2 · see citing works
Lee, B., Yu, M., Song, J. G., Lee, H., Kim, H. W., & Na, D. (2024) · Rejuvenation Research · doi:10.1089/rej.2023.0069 · Cited by 2 · see citing works
Miller, M. D., Ward, M., Keith, C. M., Patel, V. H., Haut, M. W., Wilhelmsen, K. C., Navia, O., Mehta, R. I., Marano, G., & Kiddy, A. (2024) · The American Journal of Geriatric Psychiatry Open Science Education and Practice · doi:10.1016/j.osep.2024.04.001 · Cited by 1 · see citing works
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00007-6 · Cited by 1 · see citing works
Litke, R. R., Vicari, J. M., Huang, B. T., Shapiro, L. R., Roh, K.-H., Silver, A. E., Talreja, P., Palacios, N., Yoon, Y., Kellner, C. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.12.544352 · Cited by 1 · see citing works
Potential Treatments for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00008-2
Polypharmacology in Clinical Applications: Neurological Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_6
Moncayo-Gaete, J., Mendoza-Tirado, E., Duque, L., Guapisaca, F., Narváez, M. R. A., Chiriboga-Lozada, S., Romero-Cortez, F., & Proaño, S. P. R. (2024) · Revista de la Facultad de Ciencias Médicas (Quito) · doi:10.29166/rfcmq.v49i1.5824
PREPARATION OF LIPID NANOCARRIER FORMULATIONS AND CYTOTOXICITY STUDIES OF DONEPEZIL
Demir, E., Özgenç, E., & Gündoğdu, E. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1400158
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Joodaki, M., Shirazi, M. M., & Hosseini, N. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.3.219
QbD In Solid Lipid Nanoparticles To Enhance Blood-Brain Barrier Permeation For Alzheimer’s Therapy
Bala, S., & Selvam, P. (2025) · European journal of parenteral & pharmaceutical sciences · doi:10.37521/ejpps30210
Novel benzylpiperidine -derived acetylcholinesterase inhibitors with antioxidant properties
Zuo, J., Liu, A., Wang, H., Chen, W., & Jiang, X. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144346
Mohammed, A., & hamad, E. E. (2026) · Biomedical Research and Therapy · doi:10.15419/q7by1598
Sharma, S., Sharma, U., Sethiya, N. K., & Singh, L. (2026) · Current Aging Science · doi:10.2174/0118746098373086251201095903
Recent Advances in Drug Development for the Management of Alzheimer’s Disease
Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014
Gu, Z., Luo, Y., Li, C., Li, J., Liu, P., Huang, Y. L., Chen, L., Li, Y., & He, B. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110159
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Kwon, H. S., Shin, J.-O., Park, G. U., Kim, G. H., Yang, Y., Lee, C., & Choi, H. (2026) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2026.25.4.253
- Authors
- Greig, S. L.
- Affiliations
- Springer Nature (Germany) (DE)
- Corresponding author
- Greig, Sarah L.
- ORCID
- Greig, Sarah L.
- Venue
- CNS Drugs
- Published
- 2015-10-30
- Volume
- 29
- Issue
- 11
- Pages
- 963-970
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W1957558887
- Cited by
- 69
- References
- 24
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 9 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 3 · 2015: 1
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- donepezil, Alzheimer's disease, fixed-dose combination, cholinesterase inhibitors, adjunctive therapy, bioequivalence, cognitive function, semantic processing, tolerability, drug safety
- MeSH terms
- Alzheimer Disease, Drug Combinations, Humans, Memantine, Piperidines, Clinical Trials, Phase III as Topic, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
